Trials / Completed
CompletedNCT00317044
Safety and Efficacy Study to Determine Anti-Asthmatic Effect of Esomeprazole Magnesium; Nexium Reflux Asthma
A 6-month Randomized, Double-blind, Parallel-group, Multicentre, Placebo-controlled Phase II Study to Compare Anti-asthmatic Effect and Safety of Esomeprazole (Nexium®) 40 mg Twice Daily or 40 mg Once Daily With Placebo in Adults With Asthma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 961 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether treatment with esomeprazole for 6 months will improve asthma in adult patients with moderate to severe asthma and symptoms of gastroesophageal reflux disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Esomeprazole | Esomeprazole 40 mg twice daily |
| DRUG | Esomeprazole | Esomeprazole 40 mg once daily |
| DRUG | Placebo | Placebo twice daily |
Timeline
- Start date
- 2006-04-01
- Primary completion
- 2008-07-01
- Completion
- 2008-07-01
- First posted
- 2006-04-24
- Last updated
- 2014-06-09
- Results posted
- 2014-06-09
Locations
130 sites across 14 countries: United States, Argentina, Bulgaria, Canada, Czechia, France, Germany, Hungary, Italy, Mexico, Poland, Portugal, Slovakia, Switzerland
Source: ClinicalTrials.gov record NCT00317044. Inclusion in this directory is not an endorsement.